Hot flushes are a common symptom of the menopause experienced by most of the menopausal women as a sudden feeling of warmth or heat in the body, which are usually most intense over the face, neck and chest. Hot flushes may occur on their own but are often accompanied by night sweats or excessive sweating during the day. Other causes of hot flashes include breast and prostate cancer treatments. Hormone replacement therapy (HRT) is the most effective treatment for menopausal hot flashes. However, long term HRT has an increased risk of breast cancer and risk associated with increasing age such as stroke, blood clots, and other health related problems. Estrogen and progesterone are the most common hormonal regimens used to reduce hot flashes. Estrogen is the most effective treatment for vasomotor symptoms as it reduces the severity of vasomotor symptoms, often with improvement beginning within the first week of treatment. Other drugs used for the treatment of hot flashes include combination of bazedoxifene and conjugated estrogens, certain antidepressants, and other prescription medications.
The global menopausal hot flashes therapy market segmentation is based on therapy (hormonal therapy, estrogen, progestin, combination therapy, non-hormonal therapy).
The global menopausal hot flashes therapy market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global menopausal hot flashes therapy market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global menopausal hot flashes therapy market and included in this report are Allergan plc, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk, Corporation, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.